Elusys Therapeutics Announces Publication of Data Establishing the Adult Human Dose for its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES PUBLICATION OF DATA ESTABLISHING THE ADULT HUMAN DOSE FOR ITS INHALATIONAL ANTHRAX ANTITOXIN, ANTHIM® (OBILTOXAXIMAB) INJECTION PINE BROOK, NJ, DECEMBER 20, 2016 – Elusys Therapeutics, Inc. (Elusys) today announced that the company published data and analyses used to determine the intravenous adult human dose for ANTHIM ®(obiltoxaximab) Injection, its treatment for […]

Elusys Therapeutics Announces Publication of Results from Five Clinical Trials with its Inhalational Anthrax Antitoxin ANTHIM® (Obiltoxaximab) Injection

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM FIVE CLINICAL TRIALS WITH ITS INHALATIONAL ANTHRAX ANTITOXIN, ANTHIM®(OBILTOXAXIMAB) INJECTION PINE BROOK, NJ, SEPTEMBER 14, 2016 –  Elusys Therapeutics, Inc. (Elusys) today announced that the company published data on over 450 healthy adult subjects from five clinical trials used to support recent U.S. Food and […]

Elusys Therapeutics Announces that Manuscripts for its Anthrax Antitoxin, ANTHIM® (Obiltoxaximab) Injection, have been Accepted for Publication

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS ANNOUNCES THAT MANUSCRIPTS FOR ITS ANTHRAX ANTITOXIN, ANTHIM® (OBILTOXAXIMAB) INJECTION, HAVE BEEN ACCEPTED FOR PUBLICATION — Animal Efficacy Data for Treatment and Prophylaxis — PINE BROOK, NJ, JULY 20, 2016 – Elusys Therapeutics, Inc. (Elusys) today announced that two important manuscripts describing animal efficacy of ANTHIM (obiltoxaximab) Injection in treatment and prophylaxis of […]

Elusys Therapeutics Receives FDA Approval for ANTHIM® (Obiltoxaximab) Injection for the Treatment and Prophylaxis of Inhalational Anthrax

Media Center PRESS RELEASE 2016 ELUSYS THERAPEUTICS RECEIVES FDA APPROVAL FOR ANTHIM® (OBILTOXAXIMAB) INJECTION FOR THE TREATMENT AND PROPHYLAXIS OF INHALATIONAL ANTHRAX PINE BROOK, NJ, MARCH 21, 2016 –  Elusys Therapeutics, Inc. (Elusys) today announced that the U.S. Food and Drug Administration (FDA) has approved ANTHIM (obiltoxaximab) Injection, the company’s monoclonal antibody (mAb) anthrax antitoxin. ANTHIM is indicated in adult […]